https://oncologyvoicenetwork.com/2026-04-10weekly1.0https://oncologyvoicenetwork.com/uploads/1721142865_fddc3d6cfd4c7837782d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722911738_73dd36441f72013565c2.jpgThe FDA Oncology Center of Excellence and Precision MedicineThe FDA Oncology Center of Excellence and Precision Medicinehttps://oncologyvoicenetwork.com/uploads/1721144000_49779e9a6a701d808b83.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722911011_a999dc39e81b36f1b9f4.jpgClinical Trials in Oncology and Defining BenefitClinical Trials in Oncology and Defining Benefithttps://oncologyvoicenetwork.com/uploads/1721144358_6f9280efe80919468b51.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722911503_faeb234cdbfcfb534dde.jpgStreamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research StatementStreamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statementhttps://oncologyvoicenetwork.com/uploads/1721145352_ea5d454078f376cef24e.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722911124_161bd45a5c899ad7edf9.jpgMagnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug AdministrationMagnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administrationhttps://oncologyvoicenetwork.com/uploads/1721145694_e2398d0290d9d6877b67.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722912209_cdabc16d7845ea2b06ab.jpgReverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug DevelopmentReverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Developmenthttps://oncologyvoicenetwork.com/uploads/1721146557_b6b64e28cc77be7c45b7.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722912125_8a15660a939f3044d09d.jpgChallenges and Opportunities in Dose Finding in Oncology and Immuno-oncologyChallenges and Opportunities in Dose Finding in Oncology and Immuno-oncologyhttps://oncologyvoicenetwork.com/uploads/1721149482_60aa8545d52573f029c5.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722912326_82754df0243348075849.jpgCancer research in the United States: A critical review of current status and proposal for alternative modelsCancer research in the United States: A critical review of current status and proposal for alternative modelshttps://oncologyvoicenetwork.com/uploads/1721148171_93025706cb8403b59b46.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722911888_07fde46d71f615ee6ffb.jpgEvolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and SafetyEvolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safetyhttps://oncologyvoicenetwork.com/uploads/1721150127_1283ae790c8c3d484b66.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722912482_6fd0fe9d3ea7ab626fe8.jpgOpportunities and challenges in biosimilar uptake in oncologyOpportunities and challenges in biosimilar uptake in oncologyhttps://oncologyvoicenetwork.com/uploads/1721151641_dab5445aa2fb35b387bc.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724523194_34821ff4d0211f906d0a.jpgOverview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016https://oncologyvoicenetwork.com/uploads/1721224999_557b5e343bd968288123.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724523038_b48a07d3de2d0276c0c2.pngThe Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid LeukemiaThe Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemiahttps://oncologyvoicenetwork.com/uploads/1721225721_bc369ad41f709f13f999.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724258624_b61626f1c1cb9cf0c2bc.jpgValue assessment frameworks in oncology: championing concordance through shared standardsValue assessment frameworks in oncology: championing concordance through shared standardshttps://oncologyvoicenetwork.com/uploads/1721226257_d9b5ba0653f5ec93726d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724257838_db0fc7cf5f257edebbac.jpgBiosimilars: what the oncologist should knowBiosimilars: what the oncologist should knowhttps://oncologyvoicenetwork.com/uploads/1721226960_fa150d6642771d792f0d.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724258423_4efc7c9788078bb4d994.jpgAnticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerationsAnticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerationshttps://oncologyvoicenetwork.com/uploads/1721237641_75d4000493e0d1fe3050.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724258312_af336529d830e1ccfc48.jpgRepresentation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical TrialsRepresentation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trialshttps://oncologyvoicenetwork.com/uploads/1721238448_0cb46718d2167cd719b7.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724258064_4edab4c9c9d8bac57831.jpgTiming of first-in-child trials of FDA-approved oncology drugsTiming of first-in-child trials of FDA-approved oncology drugshttps://oncologyvoicenetwork.com/uploads/1721239258_80094bb355af3e944614.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724258214_d1d2106e8c58abfe685a.jpgEstimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical TrialsEstimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trialshttps://oncologyvoicenetwork.com/uploads/1721241786_7c6c88dd81517f868481.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722912562_de1f2ad56d62939363bc.jpgCancer experts point to new advances in research and treatment: A recent report by the American Association for Cancer Research highlights unprecedented successes as well as ongoing challenges in the cancer fieldCancer experts point to new advances in research and treatment: A recent report by the American Association for Cancer Research highlights unprecedented successes as well as ongoing challenges in the cancer fieldhttps://oncologyvoicenetwork.com/uploads/1721312098_752550801dec1844b661.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722913011_5722bbff7141a488218a.jpgCancer drug development: The missing linksCancer drug development: The missing linkshttps://oncologyvoicenetwork.com/uploads/1721312618_dfcba0fa80c5a9b51102.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722913448_9fbf602c798ac3e841a0.jpgAnalysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug AdministrationAnalysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administrationhttps://oncologyvoicenetwork.com/uploads/1721313321_41868de8337c9a5899a3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724257641_6355493466091108fb21.jpgEstimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsEstimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugshttps://oncologyvoicenetwork.com/uploads/1721314225_bfd1b34d9d9d5fb5051d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722913730_24aa94a3d2d395125c1f.jpgAssociation of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled AnalysisAssociation of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysishttps://oncologyvoicenetwork.com/uploads/1723169875_f8ce47d6bbe23a90e1f3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722913985_cfb5ad6d63430a63e6d4.jpgAssessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit https://oncologyvoicenetwork.com/uploads/1721316853_bdd2f69552559dd488fd.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722914103_2c196f21e504d289c667.jpgQuantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-OncologyQuantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncologyhttps://oncologyvoicenetwork.com/uploads/1721317557_32b6ea3c6defd0f78299.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722914287_07bc4665dfb7405b65d3.jpgAn Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response RateAn Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Ratehttps://oncologyvoicenetwork.com/uploads/1721320350_c5da85e222a8d482a326.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722914376_ffa5e1377485c7e91448.jpgRecent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancerRecent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancerhttps://oncologyvoicenetwork.com/uploads/1721320948_c230ac10b80a25373042.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722914562_2f73ae3c672f2e8d9543.jpgAssessing cardiac safety in oncology drug developmentAssessing cardiac safety in oncology drug developmenthttps://oncologyvoicenetwork.com/uploads/1722093312_9f2e85adef231ad4fccf.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722914683_c4a96984f9c7edfc63a9.jpgThe evolving landscape of precision medicine in primary liver cancerThe evolving landscape of precision medicine in primary liver cancerhttps://oncologyvoicenetwork.com/uploads/1722094618_59f456d298822404c6c1.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722914887_a7abe8034a520068d7a3.jpgAddressing oncologists' gaps in the use of biosimilar productsAddressing oncologists' gaps in the use of biosimilar productshttps://oncologyvoicenetwork.com/uploads/1722095237_5d11e76666d1ee131944.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722914999_c0c7619cb18d0172c34f.jpgDose Finding in the Clinical Development of 60 US Food and Drug Administration-Approved Drugs Compared With Learning vs. Confirming RecommendationsDose Finding in the Clinical Development of 60 US Food and Drug Administration-Approved Drugs Compared With Learning vs. Confirming Recommendationshttps://oncologyvoicenetwork.com/uploads/1722095828_583cb594664995d04abb.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722915090_149fc08fb87727ca957c.jpgDefining a Clinically Meaningful Benefit in Cancer Clinical Trials: From the Perspectives of the Clinical Trialist, Patient, and SocietyDefining a Clinically Meaningful Benefit in Cancer Clinical Trials: From the Perspectives of the Clinical Trialist, Patient, and Societyhttps://oncologyvoicenetwork.com/uploads/1722096422_6bfa31741a22377d57c6.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722915385_98f6f3284ffa424624ce.jpgPediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric CancersPediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancershttps://oncologyvoicenetwork.com/uploads/1722096786_7cb89e842f3818d981a9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722915628_c7062731910646e0a4fb.jpgBiased by design? Clinical trials and patient benefit in oncologyBiased by design? Clinical trials and patient benefit in oncologyhttps://oncologyvoicenetwork.com/uploads/1722097283_25afae7b93325c22a2ad.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722915721_e609afb0fb6d7ca72fb3.jpgThe Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology MeetingsThe Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetingshttps://oncologyvoicenetwork.com/uploads/1722098379_e42d3fe825d2482dd74d.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722915885_add0c141b0cd3f201967.jpgFDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019https://oncologyvoicenetwork.com/uploads/1722098969_41615b6ea3ed7ac5c53a.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722916055_cf41c95009e92e47d721.jpgSponsorship of oncology clinical trials in the United States according to age of eligibilitySponsorship of oncology clinical trials in the United States according to age of eligibilityhttps://oncologyvoicenetwork.com/uploads/1722099525_9b6c3fb6d4078b8afe49.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722916596_a65217aaca0ac54eafb3.jpgMechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in OncologyMechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncologyhttps://oncologyvoicenetwork.com/uploads/1722104681_93ebede898bb7b0700e6.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722916884_d6dab319050df4b926e3.jpgDiscordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology CompoundsDiscordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compoundshttps://oncologyvoicenetwork.com/uploads/1722105927_1e477022056754bca299.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1722917052_d5925297c8b55071adef.jpgApproval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United StatesApproval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United Stateshttps://oncologyvoicenetwork.com/uploads/1722107243_75f0b66b3c61fe1c5259.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722917028_2bd1a922174d8a8d3a65.jpgUse of Real-World Evidence to Support FDA Approval of Oncology DrugsUse of Real-World Evidence to Support FDA Approval of Oncology Drugshttps://oncologyvoicenetwork.com/uploads/1722867026_5f52e57666bd3e66e304.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722867959_7afed64ddd56453f5a6f.jpgPotential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018https://oncologyvoicenetwork.com/uploads/1722868118_093c259fa47a373445f4.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722917507_260917fc8e22a5493a01.jpgClinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016https://oncologyvoicenetwork.com/uploads/1722886374_a0667787b08d5561ab56.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722917692_2c31c83380d14fb63ec8.jpgThe Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical IndustryThe Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industryhttps://oncologyvoicenetwork.com/uploads/1722889479_7137a915149084ce4268.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722917974_60dd4238718de4b5295f.jpgUse of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectivesUse of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectiveshttps://oncologyvoicenetwork.com/uploads/1722891031_b3bc3939832af3873116.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722918191_686004da06531f5671bd.jpgInadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuationInadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuationhttps://oncologyvoicenetwork.com/uploads/1722891461_5b6a61839fe17f4b8e38.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722918317_be93191bd9405c0e9b54.jpgFDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology DrugsFDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugshttps://oncologyvoicenetwork.com/uploads/1722891875_6b18047f6e711f7f2d83.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1722918586_be3ae01e0d0864e9b6ec.jpgOncology approvals in 2020: a year of firsts in the midst of a pandemicOncology approvals in 2020: a year of firsts in the midst of a pandemichttps://oncologyvoicenetwork.com/uploads/1723123279_19c44dc4453b7b7eaeb4.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723165171_77a45e644c216f35f661.jpgModel-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?https://oncologyvoicenetwork.com/uploads/1723123618_7aa392a13f101162c112.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723165608_141404543bd4b12ed022.jpgPatient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration PerspectivePatient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspectivehttps://oncologyvoicenetwork.com/uploads/1723124183_072bebe3d88c501cad0f.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723165586_c9140c457d0c22490a9e.jpgPatient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug AdministrationPatient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administrationhttps://oncologyvoicenetwork.com/uploads/1723124779_068f095dd4c2c4123ed5.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723165742_515ffc0654e354db607e.jpgUse of real-world evidence for oncology clinical decision making in emerging economiesUse of real-world evidence for oncology clinical decision making in emerging economieshttps://oncologyvoicenetwork.com/uploads/1723125349_da14999acd55ee8bdcde.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1723165930_06c3b8dc06ae71f4549b.jpgAssessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort studyAssessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort studyhttps://oncologyvoicenetwork.com/uploads/1723125565_219e4936b10c7187e63b.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723166133_ab4e3f7c07b03780ef48.jpgPayer perceptions of the use of real-world evidence in oncology-based decision makingPayer perceptions of the use of real-world evidence in oncology-based decision makinghttps://oncologyvoicenetwork.com/uploads/1723126218_b89aa68e7d9c65edb651.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723166224_dc8ca246a14da5a07d7c.jpgCanadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval ProgramCanadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Programhttps://oncologyvoicenetwork.com/uploads/1723126688_e473488e242c20f2477c.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723166520_ccb77b5234c28e7deb07.jpgImplications of Research Biopsies in Clinical TrialsImplications of Research Biopsies in Clinical Trialshttps://oncologyvoicenetwork.com/uploads/1723127122_941c62c7a0027ecff753.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723166720_83fefc96ada63b773944.jpgThe Inclusion of Women in Global Oncology Drug Trials Over the Past 20 YearsThe Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Yearshttps://oncologyvoicenetwork.com/uploads/1723127515_a7f9928083d5c0b5b426.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723169423_03e8d3b29970a9ada6e1.jpgRegulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational studyRegulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational studyhttps://oncologyvoicenetwork.com/uploads/1723128547_6c2ba4c2ecc65a579211.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167054_a38aa9b077d14df44d57.jpgEstimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated https://oncologyvoicenetwork.com/uploads/1723129021_a9bcbdf5401751d4bc4c.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1723167253_41aa90a07f98cbfed9d2.jpgReal-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application https://oncologyvoicenetwork.com/uploads/1723129863_049b04c9e739e1e26e73.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167370_bc02daee304c8e483316.jpgReport from American Society of Clinical Oncology Symposium 2020 and American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2021Report from American Society of Clinical Oncology Symposium 2020 and American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2021https://oncologyvoicenetwork.com/uploads/1723135047_d7fe2f8209e2567cd33d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167496_236a2084b9e78101fbf2.jpgCheckMate-067: Raising the Bar for the Next Decade in OncologyCheckMate-067: Raising the Bar for the Next Decade in Oncologyhttps://oncologyvoicenetwork.com/uploads/1723135898_5f1d8a2d6968372f2157.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167604_0f021b96f2f483b2fdeb.jpgExternal control arms in oncology: current use and future directionsExternal control arms in oncology: current use and future directionshttps://oncologyvoicenetwork.com/uploads/1723136257_2c4e3f55a60173f5a1e4.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167714_e5636d8562744c79f7ed.jpgBuilding a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing ToolsBuilding a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Toolshttps://oncologyvoicenetwork.com/uploads/1723136904_123f07d9281720e89e6e.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167784_26cd8299e4c2cb82c8d9.jpgRationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and PerspectiveRationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspectivehttps://oncologyvoicenetwork.com/uploads/1723137355_6952b75620c0c7b45603.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723167880_0baaf7718588932dc40f.jpgThe challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendationsThe challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendationshttps://oncologyvoicenetwork.com/uploads/1723151596_a8adf44bf2bfb6569f07.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1723168013_cd93f5591e0e8c537298.jpgAre the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?https://oncologyvoicenetwork.com/uploads/1723152073_6e3bc016da0759921248.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723168080_d6d2a7d29b2f7efeee2a.jpgEmbracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?https://oncologyvoicenetwork.com/uploads/1723152841_3853f466dc92235c0820.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1723168209_5c3a6d4321ff177d294f.jpgApplication of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric CancerApplication of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancerhttps://oncologyvoicenetwork.com/uploads/1723154228_6773632a011e2ae46d60.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723168352_5775f0c8b607a8131284.jpgMedical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United StatesMedical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United Stateshttps://oncologyvoicenetwork.com/uploads/1723154907_2dd5b204e19bce675cd2.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723168423_20d424b40d38a8ff7c1b.jpgTwelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented dataTwelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented datahttps://oncologyvoicenetwork.com/uploads/1723162637_47f297fa0ffed5f37929.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723168975_b156d92d675d72f71c6c.jpgFactors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from ChinaFactors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from Chinahttps://oncologyvoicenetwork.com/uploads/1723163101_3c2c620d1954bec718dd.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1723169054_9e0c2fd0d3b974b9c82c.jpgWhat is the weight of expectation bias in oncology trials?What is the weight of expectation bias in oncology trials?https://oncologyvoicenetwork.com/uploads/1723164030_b59cb0fbc763e7540793.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1723169119_7b73f479df53b2b7dcc6.jpgUS Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?https://oncologyvoicenetwork.com/uploads/1724119535_e1a09f9e268b2c86e7e7.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724241738_6b6370fdaadea3151cb3.jpgOff-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesOff-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicineshttps://oncologyvoicenetwork.com/uploads/1724119982_e79518073dbd9621374d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724241973_8ed3b8da436cbae9560e.jpgEarly phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021https://oncologyvoicenetwork.com/uploads/1724120620_34a12f7c763536b291d4.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724242040_8e784edca7c68ccfbfb5.jpgValue assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020https://oncologyvoicenetwork.com/uploads/1724120882_e3120585311f041dfe30.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724242176_c0e658259b3cfd332a3f.jpgThe correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworksThe correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworkshttps://oncologyvoicenetwork.com/uploads/1724121442_df24a7dc79cfa71da1c4.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724242417_18cf68d0dd202b2ddd11.jpgPreliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation StudyPreliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Studyhttps://oncologyvoicenetwork.com/uploads/1724122201_1371a7d9a51b0f9dffeb.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724242539_075e5f36f4d50df970d8.jpgEvaluating External Validity of Oncology Biosimilar Safety StudiesEvaluating External Validity of Oncology Biosimilar Safety Studieshttps://oncologyvoicenetwork.com/uploads/1724122805_f615b37ac5f279357475.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724243000_fb38995280d09e233683.jpgDefining the role of real-world data in cancer clinical research: The position of theDefining the role of real-world data in cancer clinical research: The position of thehttps://oncologyvoicenetwork.com/uploads/1724123167_700acc2c1a74c01e2cee.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724243097_d44401345d9202a6c0a5.jpgSingle-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefitSingle-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefithttps://oncologyvoicenetwork.com/uploads/1724123717_e637d5c43d603c15c792.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724243165_e57af6632b9861cb3eed.jpgValue assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancersValue assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancershttps://oncologyvoicenetwork.com/uploads/1724124128_e6966012196bd0c4cf16.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724243352_01e276e849a4a6074647.jpgThe Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical ResearchThe Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Researchhttps://oncologyvoicenetwork.com/uploads/pdf_697249712946c_1769097585.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724252389_59b16c89f58cf9eb0170.jpgPatient Education for Next-Generation Sequencing to Guide Cancer TherapyPatient Education for Next-Generation Sequencing to Guide Cancer Therapyhttps://oncologyvoicenetwork.com/uploads/1724449618_3c2520df6ed1d9e3b996.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724449610_6bf4b1605a1608efbd29.jpgExposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated ApprovalExposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approvalhttps://oncologyvoicenetwork.com/uploads/1724457051_41bd2d067fc10f3633a0.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724457281_17820b2e5657edd0f54d.jpgCoronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)https://oncologyvoicenetwork.com/uploads/pdf_69724978a6b4b_1769097592.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724548681_625b27af002b90d13316.jpgBiosimilar Basics for Oncology Nurses and PatientsBiosimilar Basics for Oncology Nurses and Patientshttps://oncologyvoicenetwork.com/uploads/pdf_697249813ed72_1769097601.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724546558_353300240f91e8a98400.jpgThe Practical Side of Clinical TrialsThe Practical Side of Clinical Trialshttps://oncologyvoicenetwork.com/uploads/pdf_6972498b71205_1769097611.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724603290_5a8810e4a21cb2a20764.jpgAdvanced Practitioners’ Role in ResearchAdvanced Practitioners’ Role in Researchhttps://oncologyvoicenetwork.com/uploads/pdf_6972498c4b0fa_1769097612.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724605254_c1a7d309ddcceed97aa0.jpgAdvancing Clinical Trial EquityAdvancing Clinical Trial Equityhttps://oncologyvoicenetwork.com/uploads/1724617184_566112ac57ff3c3a7e29.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724617968_ed3a2e45347964698b41.jpgTowards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intentTowards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intenthttps://oncologyvoicenetwork.com/uploads/1724618345_400bb3fc28a9d8a26261.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724618576_9effc5764d82b4502adb.jpgBiosimilars in Oncology: Latest Trends and Regulatory StatusBiosimilars in Oncology: Latest Trends and Regulatory Statushttps://oncologyvoicenetwork.com/uploads/1724618953_9f7a4e5c3bb46bc3560d.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724619194_9ca842579f9bce5fce48.jpgMethodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit ScaleMethodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scalehttps://oncologyvoicenetwork.com/uploads/1724619357_be89c5ae81fe0009b1d9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724619574_7ad2f7cd85e11c11cd85.jpgAssociation between control group therapy and magnitude of clinical benefit of cancer drugsAssociation between control group therapy and magnitude of clinical benefit of cancer drugshttps://oncologyvoicenetwork.com/uploads/1724619644_807c979beb10d6e3f4a4.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724619950_1f39805d93c39ae92251.jpgIdentification of Barriers Preventing Biosimiliar Oncology Medication AdoptionIdentification of Barriers Preventing Biosimiliar Oncology Medication Adoptionhttps://oncologyvoicenetwork.com/uploads/1724620021_08e672a54ad494a54efa.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724620275_a3c82c8b993afd032883.jpgAssociation Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020https://oncologyvoicenetwork.com/uploads/1724620657_6e7c4b1ed830a0458556.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724620728_32e68759032b303bffd4.jpgOncology biosimilars: New developments and future directionsOncology biosimilars: New developments and future directionshttps://oncologyvoicenetwork.com/uploads/1724625197_c628aaeafe1cba430405.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724625304_b48ad4bf77d674bd6d1a.jpgResearch Highlights In The News From ESMOResearch Highlights In The News From ESMOhttps://oncologyvoicenetwork.com/uploads/1724625661_439dc119d2f7f1bba98d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724625943_a7adbd2f2d617b06ec63.jpgFDA validation of surrogate endpoints in oncology: 2005–2022FDA validation of surrogate endpoints in oncology: 2005–2022https://oncologyvoicenetwork.com/uploads/1724626148_223faca592b563a39e1c.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724626316_0ce19d849f6f6a2a9d92.jpgHow do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of CancerHow do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancerhttps://oncologyvoicenetwork.com/uploads/1724626548_cdf163b66ffff974e166.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724626644_e24e1b9cd924287f207a.jpgRecent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated ApprovalRecent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approvalhttps://oncologyvoicenetwork.com/uploads/1724626818_07ffe6d387bbb25ba672.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724626941_2e0f571440f52808aed0.jpgOverall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020https://oncologyvoicenetwork.com/uploads/1724627192_8f89cd2e9482b442d5b2.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724627316_b467761259fed264b68c.jpgAudit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug AdministrationAudit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administrationhttps://oncologyvoicenetwork.com/uploads/1724627699_a218944cd9438b4a0cad.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724627743_ebb95e32124e7b697514.jpgUptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care SystemsUptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systemshttps://oncologyvoicenetwork.com/uploads/1724628087_f8980d9ac973fc08eac9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724628217_f01303d6efa569e7b637.jpgA Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation StudyA Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation Studyhttps://oncologyvoicenetwork.com/uploads/1724628388_23f5cb2551d4966133df.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724628547_205957f71503b2b935ca.jpgClinical benefit of cancer drugs approved in Switzerland 2010–2019Clinical benefit of cancer drugs approved in Switzerland 2010–2019https://oncologyvoicenetwork.com/uploads/1724628039_7be3e44caaac88fda9f8.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724628315_2d63749222ec08c24a69.jpgComparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit ScaleComparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scalehttps://oncologyvoicenetwork.com/uploads/1724628815_56f5480dd5e5ea26564d.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724629111_98f863916a3603303314.jpgCost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022https://oncologyvoicenetwork.com/uploads/1724631029_8e235cc84d891a36979e.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724630994_d765663479e13a8aedb4.jpgMedian Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?https://oncologyvoicenetwork.com/uploads/1724631394_9842e0f80e557ee96610.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724631719_ee75659e6be043b4c53b.jpgLevel of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvalsLevel of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvalshttps://oncologyvoicenetwork.com/uploads/1724631969_1e978e94795669285fb1.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1724632531_1ab64d7ff91cc71ba149.jpgFirst person profile: Leslie Bernstein, PhD: An epidemiologist known for her groundbreaking discoveries about breast cancer, Dr. Bernstein continues to push the field forwardFirst person profile: Leslie Bernstein, PhD: An epidemiologist known for her groundbreaking discoveries about breast cancer, Dr. Bernstein continues to push the field forwardhttps://oncologyvoicenetwork.com/uploads/1724632867_3c74c8d6a7a6017f359d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724633524_5278873d493cacf5f247.jpgEarly-drug development in the era of immuno-oncology: are we ready to face the challenges?Early-drug development in the era of immuno-oncology: are we ready to face the challenges?https://oncologyvoicenetwork.com/uploads/1724633634_e076da9fc25ff1ab74e8.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724633952_040e446431167cc443a5.jpgThe rise of oncology biosimilars: from process to promiseThe rise of oncology biosimilars: from process to promisehttps://oncologyvoicenetwork.com/uploads/1724634097_03237ee759e98d8e6472.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1724634516_25ff50ab418fe0d9f229.jpgAssociation of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug IndicationsAssociation of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indicationshttps://oncologyvoicenetwork.com/uploads/1743773555_86473e9e671ecb3b6e5a.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743774291_2847f43f96ef92bb106b.jpgPrediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2https://oncologyvoicenetwork.com/uploads/1743774820_c75b7fa8b3a9145476ac.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743775149_3f0a2636c30242d54ab9.jpgLiquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyLiquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncologyhttps://oncologyvoicenetwork.com/uploads/1743775332_4c1cc90c52fa5a16a1de.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743775923_fdc1880e2a350938666f.pngNew Realities of Phase I Clinical Trials in the Era of New Realities of Phase I Clinical Trials in the Era of https://oncologyvoicenetwork.com/uploads/1743776176_aa96e02e54ec307fef05.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743776354_572e7797939d2f9daf9d.jpgFirst person profile: Supriya G. Mohile, MD, MS: A respected geriatric oncologist, Dr. Mohile has conducted innovative research on improving care for older patients with cancerFirst person profile: Supriya G. Mohile, MD, MS: A respected geriatric oncologist, Dr. Mohile has conducted innovative research on improving care for older patients with cancerhttps://oncologyvoicenetwork.com/uploads/1743776628_d30ca7945d71b98ed734.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743777127_efb0a9a3bcc97a7d5c84.jpgPublication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigationPublication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigationhttps://oncologyvoicenetwork.com/uploads/1743777382_35d3bbb782fd38e1b050.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743777993_d7c55e60b8334f97a233.jpgPivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug DevelopmentPivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Developmenthttps://oncologyvoicenetwork.com/uploads/1743778497_682ff324b2b7123c3a11.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743779032_850a88776a35abb45afb.jpgMandatory Research Biopsy Requirements Delay Initiation of Clinical TrialsMandatory Research Biopsy Requirements Delay Initiation of Clinical Trialshttps://oncologyvoicenetwork.com/uploads/1743779471_8add78b841358c7334e3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743779742_85833a0175496e0db3f8.jpgValue assessment of oncology drugs using a weighted criterion-based approachValue assessment of oncology drugs using a weighted criterion-based approachhttps://oncologyvoicenetwork.com/uploads/1743779903_027ad145b07c6aa57072.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743780250_60ff1acfbe8b71754f5f.jpgOutcome measures for oncology alternative payment models: practical considerations and recommendationsOutcome measures for oncology alternative payment models: practical considerations and recommendationshttps://oncologyvoicenetwork.com/uploads/1743780679_724a1a590bce468e815f.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743781934_f945729e52a31c06884a.jpgReal-World Evidence in Oncology: Opportunities and LimitationsReal-World Evidence in Oncology: Opportunities and Limitationshttps://oncologyvoicenetwork.com/uploads/1743790210_183deec02366fe9a0db3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743791440_e118da0889141867f4a5.jpgThe pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a reviewThe pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a reviewhttps://oncologyvoicenetwork.com/uploads/1743792051_584a6811a5fa6087a11f.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1743792165_5d781d96d99b2e76f132.jpgRise of Antibody-Drug Conjugates: The Present and FutureRise of Antibody-Drug Conjugates: The Present and Futurehttps://oncologyvoicenetwork.com/uploads/1744032644_1f8ac23680093cf1d1c1.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1744033649_3f108fb936a37823fd44.jpgDeveloping a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaborationDeveloping a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaborationhttps://oncologyvoicenetwork.com/uploads/1744034817_d8f56410a1cc826bfad0.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1744034661_a963d2300e099a63ef8a.jpgPrecision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gapsPrecision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gapshttps://oncologyvoicenetwork.com/uploads/1744035476_2819e39f57fcb29512d9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1744036037_edfedfc7a19aa61334cc.jpgEHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignanciesEHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancieshttps://oncologyvoicenetwork.com/uploads/1744036568_f499aee6488ae421b6c9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1744036883_0b8e8cb21ad6e859131b.jpgIn Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018https://oncologyvoicenetwork.com/uploads/1744037099_28c54de42db48b2e01f6.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1744037776_f8921e6c5a072eecd8e0.jpgPatient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort studyPatient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort studyhttps://oncologyvoicenetwork.com/uploads/1745511688_78b15e2451d1f274b980.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745512210_ae4cc60f6cc3cf52a432.jpgPublicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015https://oncologyvoicenetwork.com/uploads/1745512570_682891c37091475358e5.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1745512864_03d5ae2fec844d5e14b4.jpgAccess to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group AnalysisAccess to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysishttps://oncologyvoicenetwork.com/uploads/1745513298_c8d12972541a67934359.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745513264_af44818d2a092fdc1f4b.jpgProportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately ApprovedProportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approvedhttps://oncologyvoicenetwork.com/uploads/1745513691_c2cd4ef3283f05b4e8d2.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745514691_ba01fa37af42218c22cf.jpgAssessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017https://oncologyvoicenetwork.com/uploads/1745515020_c32101bb619a1bd845c6.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1745515339_13c993afb1a5142315e0.jpgThe Oncology Data Network (ODN): Methodology, Challenges, and AchievementsThe Oncology Data Network (ODN): Methodology, Challenges, and Achievementshttps://oncologyvoicenetwork.com/uploads/1745517674_f62bbfec6b4b1a4e1f0a.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745517799_bfbdd01a95511e0f7614.jpgSponsorship of oncology clinical trials in the United States according to age of eligibilitySponsorship of oncology clinical trials in the United States according to age of eligibilityhttps://oncologyvoicenetwork.com/uploads/1745518180_fa79b409130cce9fdc92.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745518531_fd1bbc9412e3da259c59.jpgThe regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulationThe regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulationhttps://oncologyvoicenetwork.com/uploads/1745518746_a9d5429fc6911c52a29d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745518654_ad76463511d8202fe110.jpgComment on: Oncology research in Saudi Arabia over a 10-year period. A synopsisComment on: Oncology research in Saudi Arabia over a 10-year period. A synopsishttps://oncologyvoicenetwork.com/uploads/1745521014_3a63f038a3a607aa885a.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1745520954_8d62242d245ce4fbc2c3.jpgReal-World Evidence: Bridging Gaps in Evidence to Guide Payer DecisionsReal-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisionshttps://oncologyvoicenetwork.com/uploads/1746276158_8a34b45cec1f636710b9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747328529_3988a4b0cc77ae9bf3a8.jpgCharacterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and ProspectsCharacterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospectshttps://oncologyvoicenetwork.com/uploads/1746276861_01efd8d30c1c32ac8e0f.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747328588_b60125435d8ffd8d8f6b.jpgClinical development success rates and social value of pediatric Phase 1 trials in oncologyClinical development success rates and social value of pediatric Phase 1 trials in oncologyhttps://oncologyvoicenetwork.com/uploads/1746281647_c004fb9795373777a511.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747328630_93c479205fb95c62b032.jpgTumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future OpportunitiesTumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunitieshttps://oncologyvoicenetwork.com/uploads/1746452801_60cb7c6ef0a379c32ad1.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747328713_b9287a5cadb55f162717.jpgBiosimilars in oncology: key role of nurses in patient educationBiosimilars in oncology: key role of nurses in patient educationhttps://oncologyvoicenetwork.com/uploads/1746453792_8a4514d28dc6355c8366.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747328759_8df55dedba9d47f853be.jpgQuantitative Translation in Immuno-Oncology Research and DevelopmentQuantitative Translation in Immuno-Oncology Research and Developmenthttps://oncologyvoicenetwork.com/uploads/1746454967_e5b78bce3434767d0dfc.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747328808_e3fdb5afa91797f3be09.jpgComparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United StatesComparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United Stateshttps://oncologyvoicenetwork.com/uploads/1746456159_8c9bf8af1cb0aa1a6617.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1746456941_3b280c972a7814efba5d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747328918_8d182e00f679312d0fcb.jpgPediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future PerspectivesPediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectiveshttps://oncologyvoicenetwork.com/uploads/1746457801_7d731d79e5fe857e9c22.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747329175_7f065456a80b7f287c7a.jpgPast, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of CancerPast, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancerhttps://oncologyvoicenetwork.com/uploads/1746459700_08c8ab548b1fc4b4c3b9.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747329426_58d03a42dc99b101c0a0.jpgClinical benefit of immune checkpoint inhibitors approved by US Food and Drug AdministrationClinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administrationhttps://oncologyvoicenetwork.com/uploads/1746460218_e07ba03d7a3aa2b7cc60.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747329378_1cf059037f67e8b3a7f3.jpgQuantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and OpportunitiesQuantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunitieshttps://oncologyvoicenetwork.com/uploads/1746460432_6d33edc8d769c72178ee.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747329518_89d2c1c79478c3f99d6e.jpgProfessional Medical Writer Assistance in Oncology Clinical TrialsProfessional Medical Writer Assistance in Oncology Clinical Trialshttps://oncologyvoicenetwork.com/uploads/1746461800_3e0a7620584efb7770f3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747329577_8598e578f5d1e1149be4.jpgLessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1https://oncologyvoicenetwork.com/uploads/1746462302_d838f0c38d3e52624a0c.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747329694_d58a87b0c46b1ca519e8.jpgApplication of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapiesApplication of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapieshttps://oncologyvoicenetwork.com/uploads/1746462562_f0c2e32c901dd536e667.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747329777_92e55bf14b5cd1fefd13.jpgA Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to MeasureA Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measurehttps://oncologyvoicenetwork.com/uploads/1746463112_08b2d5d993525af3f64d.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747329903_564318d10bda561c61d9.jpgLeveraging existing data to contextualize phase II clinical trial findings in oncologyLeveraging existing data to contextualize phase II clinical trial findings in oncologyhttps://oncologyvoicenetwork.com/uploads/1746464051_e722e28a10f415853f1e.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747330059_3e72d7d36c62c64cc18c.jpgLiquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyLiquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncologyhttps://oncologyvoicenetwork.com/uploads/1746464250_40416042e09727154074.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747330148_6cc8bd3f9811489c3d72.jpgAdvances and Challenges in Pediatric and Childhood CancersAdvances and Challenges in Pediatric and Childhood Cancershttps://oncologyvoicenetwork.com/uploads/1746464625_3af174ae4c8b67182cdc.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747330493_cca7742ee4cad51fea30.jpgSeven decades of chemotherapy clinical trials: a pan-cancer social network analysisSeven decades of chemotherapy clinical trials: a pan-cancer social network analysishttps://oncologyvoicenetwork.com/uploads/1746465280_2d5f52c2c9014e52b4a3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747330674_575b5bbaa2508fcae3bc.jpgSafeguarding cancer research funding by European charities amidst the COVID-19 pandemicSafeguarding cancer research funding by European charities amidst the COVID-19 pandemichttps://oncologyvoicenetwork.com/uploads/1746466072_4ca060af7521d2318d26.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747330775_e559d8f943770deacad4.jpgFirst person profile: William Sellers, MDFirst person profile: William Sellers, MDhttps://oncologyvoicenetwork.com/uploads/1746466484_0a4ae54b10c85d913b49.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747330841_9c89d9b725ae39251c5d.jpgA narrative review of biosimilars: a continued journey from the scientific evidence to practice implementationA narrative review of biosimilars: a continued journey from the scientific evidence to practice implementationhttps://oncologyvoicenetwork.com/uploads/1746466930_87a8e38e982b7ca6e636.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747330900_7c64734a92ed44a25435.jpgConfounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncologyConfounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncologyhttps://oncologyvoicenetwork.com/uploads/1746469578_ef69bddf1f2a35d8c9f5.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747330966_832a72b671d20f23c709.jpgLoose Regulatory Standards Portend a New Era of Imprecision OncologyLoose Regulatory Standards Portend a New Era of Imprecision Oncologyhttps://oncologyvoicenetwork.com/uploads/1746469971_f9cd1aa2a87ea373a337.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747331159_41e84bbe072c4415db20.jpg“Oncometabolism: The switchboard of cancer: An editorial”“Oncometabolism: The switchboard of cancer: An editorial”https://oncologyvoicenetwork.com/uploads/1746470337_bbae3a41e7772aad4770.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747331223_b841334159ca21771e37.jpgFinding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?https://oncologyvoicenetwork.com/uploads/1747320053_6f0fd9c4ed88b734fc0c.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747331328_9ef7b348e4c2a28b21cd.jpgAccelerated drug approvals in oncology: Pros and consAccelerated drug approvals in oncology: Pros and conshttps://oncologyvoicenetwork.com/uploads/1747320769_213c0308d971329feb05.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747331427_399f260ccb9c1684d87d.jpgAssessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic ReviewAssessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Reviewhttps://oncologyvoicenetwork.com/uploads/1747321213_b4a3499cdb7d956b6f53.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747321420_691faddf2162e90bb2a3.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747322058_290cf3917103397f2ff2.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747331488_0a94ce09a70d6366e506.jpgDoes biomarker use in oncology improve clinical trial failure risk? A large-scale analysisDoes biomarker use in oncology improve clinical trial failure risk? A large-scale analysishttps://oncologyvoicenetwork.com/uploads/1747322316_01428067cde73f818a18.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747331571_520f53b4649badbe1aa4.jpgAre Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?https://oncologyvoicenetwork.com/uploads/1747323119_d1dd7027615f14cf26d4.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747331676_637bdfc2c363208e9f32.jpgAdvances in basic research in oncology in 2020: Bridging basic science and clinical careAdvances in basic research in oncology in 2020: Bridging basic science and clinical carehttps://oncologyvoicenetwork.com/uploads/1747323506_b80946bd27dba37ed6d1.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747331752_87c9aa2c0d5022391daa.jpgVirtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future DirectionsVirtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directionshttps://oncologyvoicenetwork.com/uploads/1747324022_e5bf38ac525e5fed9d78.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/1747331860_22c155aad9847a19dc1b.jpgComparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearsComparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearshttps://oncologyvoicenetwork.com/uploads/1747325561_c85d631ff74f5a08269b.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747331921_fd36a18b51b4c8cf5b0f.jpgUpdated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020https://oncologyvoicenetwork.com/uploads/1747325905_bf72f962847bd29b485c.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747332107_43832673862a973480b7.jpgBiases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringBiases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringhttps://oncologyvoicenetwork.com/uploads/1747341821_b915a5546e6a6d2c1fe2.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1747342253_e26d63d0c258af4e235a.jpgCancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled TrialsCancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trialshttps://oncologyvoicenetwork.com/uploads/1751142120_b4ac786533b83af52fba.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1751142303_f06f82d33886307c2196.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/pdf_697249a49f10f_1769097636.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/1751734362_8a7d5650d973f4841ad5.pngExpert perspectives live from ASCO® 2025Expert perspectives live from ASCO® 2025https://oncologyvoicenetwork.com/uploads/pdf_697249a8d2fea_1769097640.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/featured_697249a7f2477_1769097639.jpgClinical Educator Oncology Program Improves Adherence by 29%​Clinical Educator Oncology Program Improves Adherence by 29%​https://oncologyvoicenetwork.com/uploads/pdf_697249aa6c06e_1769097642.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/featured_697249a9ef057_1769097641.jpgVirtual Oncology MSL Team Increases KOL Engagement by 120%Virtual Oncology MSL Team Increases KOL Engagement by 120%https://oncologyvoicenetwork.com/uploads/1770755174_1a0ffac3ba0932f68010.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/featured_698bac7fd2045_1770761343.jpgDriving Therapeutic Impact: A Novel Model for Strategic Medical Affairs IntegrationDriving Therapeutic Impact: A Novel Model for Strategic Medical Affairs Integrationhttps://oncologyvoicenetwork.com/uploads/1770930407_abfd640a5bc533a990dc.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/featured_698e3e7aabb08_1770929786.jpgBusiness Acumen Is Not Strategic JudgmentBusiness Acumen Is Not Strategic Judgmenthttps://oncologyvoicenetwork.com/uploads/1770930129_d1b0818d1964109fa263.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/featured_698e3fa1a76e9_1770930081.jpgLaunch Readiness Is an Organisational CapabilityLaunch Readiness Is an Organisational Capabilityhttps://oncologyvoicenetwork.com/uploads/1770930299_6a6e53610533fa73a373.pdf2026-04-09daily0.7https://oncologyvoicenetwork.com/uploads/featured_698e40726ab44_1770930290.jpgMedical Judgment at the Point of DecisionMedical Judgment at the Point of Decisionhttps://oncologyvoicenetwork.com/uploads/1775171077_2e4739c78e4c9bed06ab.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/featured_69cef2f22b7aa_1775170290.jpgLarge pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff loomsLarge pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff loomshttps://oncologyvoicenetwork.com/uploads/1775171968_0d7d214eeac3af9cf8b7.pdf2026-04-10daily0.7https://oncologyvoicenetwork.com/uploads/featured_69cefa39d7d50_1775172153.jpgReinvent innovation and become an R&D front-runner by 2030Reinvent innovation and become an R&D front-runner by 2030